Drug intelligence / Profile preview

BQ123 + L-NMMA

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

BQ123 + L-NMMA is a combination of two pharmacological agents used primarily in research settings. BQ123 is a selective endothelin-A (ETA) receptor antagonist that blocks the vasoconstrictor effects of endothelin-1. L-NMMA (NG-monomethyl-L-arginine) is a competitive inhibitor of nitric oxide synthase (NOS) that reduces nitric oxide production. When administered together, these compounds allow researchers to study the interactions between the endothelin and nitric oxide pathways in regulating vascular function, particularly in the renal and systemic circulation.

Targets

EDNRA (Endothelin receptor type A)NOS1 (nNOS)

Beyond the preview

Go deeper on BQ123 + L-NMMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BQ123 + L-NMMA.

Explore the full profile